ReviewCellular oncology (Dordrecht, Netherlands)2022
Glioblastoma, from disease understanding towards optimal cell-based in vitro models.
Review in Cellular oncology (Dordrecht, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Selective Cytotoxic and Redox-Associated Effects of Plant-Derived Terpenoids in Human Glioblastoma Cells.Cell biochemistry and biophysics · 2026Article
- Impact of static and dynamic magneto-mechanical stimulation with vortex microdiscs on glioblastoma cells cultured on 2D substrates with physiological stiffness.Nanoscale advances · 2026Article
- Neuropilin-1-Targeted Cell-Penetrating Tandem Peptide-Drug Conjugate Exhibits Potent In Vivo Antiglioma and Antiangiogenic Activity.Journal of medicinal chemistry · 2026Article
- SHH pathway inhibition and astrocyte co-culture induce distinct responses in glioblastoma and cancer stem cells.Scientific reports · 2026Article
- Exploring Neural Stem Cell Therapies as Innovative Treatments for Glioblastoma.Cellular and molecular neurobiology · 2025Review
- Modeling Glioblastoma with Brain Organoids: New Frontiers in Oncology and Space Research.International journal of molecular sciences · 2025Review
- Review
- 3D Brain Vascular Niche Model Captures Glioblastoma Infiltration, Dormancy, and Gene Signatures.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Assembly of glioblastoma tumoroids and cerebral organoids: a 3D in vitro model for tumor cell invasion.Molecular oncology · 2025Article
- Article
- Isoform-specific vs. pan-histone deacetylase inhibition as approaches for countering glioblastoma: anFrontiers in oncology · 2025Article
- Regression and machine learning approaches identify potential risk factors for glioblastoma multiforme.Brain communications · 2025Article
- A Versatile Microfluidic Device System that Lacks a Synthetic Extracellular Matrix Recapitulates the Blood-Brain Barrier and Dynamic Tumor Cell Interaction.Bioengineering (Basel, Switzerland) · 2024Article
- Challenges and Promise for Glioblastoma Treatment through Extracellular Vesicle Inquiry.Cells · 2024Review
- Review
- USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target.Cell death discovery · 2023Review
- Biomaterial-basedCancer pathogenesis and therapy · 2023Review
- Article
- Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours.The journal of pathology. Clinical research · 2023Review
- Molecular landscapes of glioblastoma cell lines revealed a group of patients that do not benefit fromFrontiers in neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma (GBM) patients are notoriously difficult to treat and ultimately all succumb to disease. This unfortunate scenario motivates research into better characterizing and understanding this disease, and into developing novel research tools by which potential novel therapeutics and treatment options initially can be evaluated pre-clinically. Here, we provide a concise overview of glioblastoma epidemiology, disease classification, the challenges faced in the treatment of glioblastoma and current novel treatment strategies. From this, we lead into a description and assessment of advanced cell-based models that aim to narrow the gap between pre-clinical and clinical studies. Such in vitro models are required to deliver reliable and meaningful data for the development and pre-validation of novel therapeutics and treatments.
conclusionsThe toolbox for GBM cell-based models has expanded substantially, with the possibility of 3D printing tumour tissues and thereby replicating in vivo tissue architectures now looming on the horizon. A comparison of experimental cell-based model systems and techniques highlights advantages and drawbacks of the various tools available, based on which cell-based models and experimental approaches best suited to address a diversity of research questions in the glioblastoma research field can be selected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.